Quarterly report pursuant to Section 13 or 15(d)

Organization and Summary of Significant Accounting Policies - Additional Information (Detail)

v3.23.3
Organization and Summary of Significant Accounting Policies - Additional Information (Detail)
$ in Thousands
3 Months Ended 9 Months Ended
Aug. 11, 2023
Sep. 30, 2023
USD ($)
Institution
Sep. 30, 2022
USD ($)
Sep. 30, 2023
USD ($)
Institution
Sep. 30, 2022
USD ($)
Dec. 31, 2022
USD ($)
Organization And Summary Of Significant Accounting Policies [Line Items]            
Reverse stock split ratio 0.66          
Accumulated deficit   $ (448,944)   $ (448,944)   $ (444,768)
Cash and cash equivalents   15,811 $ 22,277 15,811 $ 22,277 32,190
Restricted cash included in other assets   $ 2,315 $ 2,489 $ 2,315 $ 2,489 $ 2,500
Restricted Cash and Cash Equivalents, Noncurrent, Statement of Financial Position [Extensible Enumeration]   Other assets Other assets Other assets Other assets Other assets
Number Of Financial Institutions | Institution   2   2    
Revenue | Concentration of Credit Risk and Other Risks and Uncertainties | Takeda Pharmaceuticals Inc            
Organization And Summary Of Significant Accounting Policies [Line Items]            
Percentage of total revenues   0.00% 0.00% 0.00% 15.00%  
Revenue | Concentration of Credit Risk and Other Risks and Uncertainties | Bristol Myers Squibb            
Organization And Summary Of Significant Accounting Policies [Line Items]            
Percentage of total revenues   84.00% 100.00% 91.00% 85.00%